A Multicenter, Double-Blind, Randomized, Cross-Over Study to Investigate the Efficacy of Gynodian Depot i.m. Compared to 4 mg Estradiol Valerate i.m. Both Given Every Four Weeks for Five Months Combined With 5 mg Medroxyprogesterone Acetate Orally in Postmeno-Pausal Women With Impaired Well-Being, Mood and Sexuality.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Estradiol valerate; Estradiol valerate/prasterone enantate; Medroxyprogesterone
- Indications Menopausal syndrome
- Focus Therapeutic Use
- 30 Dec 2014 Biomarkers information updated
- 20 May 2009 Bayer Schering Pharma added as trial affiliate and lead trial centre as reported by ClinicalTrials.gov.
- 20 May 2009 Actual end date (Apr 2004) added as reported by ClinicalTrials.gov.